|Bid||163.69 x 800|
|Ask||163.71 x 1200|
|Day's range||163.33 - 165.76|
|52-week range||133.65 - 179.92|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||24.46|
|Earnings date||25 Jan 2022|
|Forward dividend & yield||4.24 (2.56%)|
|Ex-dividend date||22 Nov 2021|
|1y target est||188.82|
University Hospital CEO and Fmr. Health Commissioner of New Jersey Dr. Shereef Elnahal joins the Yahoo Finance Live panel to discuss the latest outlook for COVID-19 as health officials continue to debate vaccine booster shots.
Taylor Carmichael (Novavax): Novavax's COVID-19 vaccine is still not on the market anywhere, which has made the stock a real wild ride for investors. The vaccine specialist started off 2020 so small it almost qualified as a micro-cap, with its stock priced at $4 a share. When COVID-19 hit, however, the stock took off.
Style Box ETF report for DLN